Congenital structural anomalies in offspring of women with epilepsy - A population-based cohort study in Finland

International Journal of Epidemiology

Volumn 35, Issue 2, 2006, Pages 280-287

  Artama, Miia ^a   Ritvanen, Annukka ^b   Gissler, Mika ^b   Isoj̈rvi, Jouko ^c   Auvinen, Anssi ^a,d  

^a UNIVERSITY OF TAMPERE   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Children; Cohort studies; Congenital anomalies; Epilepsy; Prevalence

Indexed keywords

ANTICONVULSIVE AGENT; VALPROIC ACID;

DISEASE PREVALENCE; HEALTH RISK; MATERNAL HEALTH;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONGENITAL MALFORMATION; CONTROLLED STUDY; DATA BASE; DRUG COST; EPILEPSY; FEMALE; FINLAND; GENITAL MALFORMATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEWBORN; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROGENY; REIMBURSEMENT; RISK ASSESSMENT; RISK FACTOR; SPINA BIFIDA;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTICONVULSANTS; COHORT STUDIES; EPILEPSY; FEMALE; FINLAND; GENITALIA; HUMANS; INFANT, NEWBORN; MATERNAL AGE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; PREVALENCE; SPINAL DYSRAPHISM;

EURASIA; EUROPE; FINLAND; NORTHERN EUROPE; SCANDINAVIA;

EID: 33645834956     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyi234     Document Type: Article

References (37)

1. Meadow SR. Anticonvulsant drugs and congenital abnormalities. Lancet 1968;2:1296.
2. Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr 1975;87:285-90.
3. DiLiberti JH, Farndon PA, Dennis NR, Curry CJ. The fetal valproate syndrome. Am J Med Genet 1984;19:473-81.
4. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324:674-77.
5. Robert E, Guibaud P. Maternal valproic add and congenital neural tube defects. Lancet 1982;320:937.
6. Kaneko S, Battino D, Andermann E et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999;33:145-58.
7. Holmes LB, Harvey EA, Coull BA et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001;344:1132-38.
8. Canger R, Battino D, Canevini MP et al. Malformations in offspring of women with epilepsy: A prospective study. Epilepsia 1999;40: 1231-36.
9. Kelly TE, Rein M, Edwards P. Teratogenicity of anticonvulsant drugs IV. The association of clefting and epilepsy. Am J Med Genet 1984;19:451-58.
10. Friis ML, Holm NV, Sindrup EH, Fogh-Andersen P, Hauge M. Facial clefts in sibs and children of epileptic patients. Neurology 1986;36: 346-50.
11. Zahn CA, Morrell MJ, Collins SD, Labiner DM, Yerby MS. Management issues for women with epilepsy: A review of the literature. Neurology 1998;51:949-56.
12. Durner M, Greenberg DA, Delgado-Escueta AV. Is there a genetic relationship between epilepsy and birth defects. Neurology 1992;42 (suppl. 5):63-67.
13. Källén B. Epidemiology of human reproduction. London: CRC Press, 1988, pp. 133-39.
14. Battino D. Assessment of teratogenic risk. Epilepsy Res 2001;45: 171-73.
15. Lindhout D, Meinardi H, Barth PG. Hazards of fetal exposure to drug combinations. In: Janz D, Dam M, Richens A, Bossi L, Helge H (eds). Epilepsy, Pregnancy, and the Child. 2nd edn. New York: Raven Press, 1982, pp. 275-81.
16. Olafsson E, Hallgrimsson JT, Hauser WA, Ludvigsson P, Gudmundsson G. Pregnancies of women with epilepsy: A population-based study in Iceland. Epilepsia 1998;39:887-92.
17. Martikainen J, Rajaniemi S. Drug reimbursement systems in EU Member States, Iceland and Norway. The Social Insurance Institution, Finland, Social Security and Health Reports 54. Helsinki, 2002.
18. Ritvanen A, Sirkiä S. Congenital anomalies 1993-2001 and preliminary data for 2002. Statistical summary 16/2004. National Research and Development Centre for Welfare and Health. Helsinki, 2004 [cited 2004 Dec 8]. Available at: http://www.stakes.info/files/pdf/tilastotiedotteet/ Tt16_04.pdf.
19. European Registration of Congenital Anomalies (EUROCAT). EUROCAT Guide 1.2. Instructions for the registration of congenital anomalies [cited 2004 Sept 23]. Available at: http://www.eurocat.ulster.ac.uk/pdf/ guide1_2.pdf.
20. Cytel Software Corporation. LogXact Version 4 for Windows. Cambridge, MA; 1999.
21. StataCorp. Stata 7. College Station, Texas: Stata Corporation, 2001.
22. Wide K, Winbladh B, Källén B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: A nation-wide, population-based register study. Acta Paediatr 2004;93:174-76.
23. Samrén EB, van Duijn CM, Koch S et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: A joint European prospective study on human teratogenesis associated with maternal epilepsy. Epilepsia 1997;38:981-90.
24. Samrén EB, van Duijn CM, Christiaens GCML, Holman A, Lindhout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999;46:739-46.
25. Katz JM, Pacia SV, Devinsky O. Current management of epilepsy and pregnancy: Fetal outcome, congenital malformation, and developmental delay. Epilepsy Behav 2001;2:119-23.
26. Yerby MS, Leavitt A, Erickson DM et al. Antiepileptics and the development of congenital anomalies. Neurology 1992;42 (suppl. 5): 132-40.
27. European Registration of Congenital Anomalies (EUROCAT) [homepage on the internet]. EUROCAT WHO Collaborating Centre for the Epidemiology Surveillance of Congenital Anomalies. Annual Report 2003 [cited 2005 Feb 1]. Available at http://www.eurocat.ulster.ac.uk/pdf/ EUROCAT%20Annual%20Report%202003%20for%20WHO.pdf.
28. Annegers JF, Hauser WA. The frequency of congenital malformations in relatives of patients with epilepsy. In: Janz D, Dam M, Richens A, Bossi L, Helge H (eds). Epilepsy, Pregnancy, and the Child. 2nd edn. New York: Raven Press, 1982, pp. 267-73.
29. Janz D. On major malformations and minor anomalies in the offspring of parents with epilepsy: Review of the literature. In: Janz D, Dam M, Richens A, Bossi L, Helge H (eds). Epilepsy, Pregnancy, and the Child. 2nd edn. New York: Raven Press, 1982, pp. 211-22.
30. Battino D, Kaneko S, Andermann E et al. Intrauterine growth in the offspring of epileptic women: A prospective multicenter study. Epilepsy Res 1999;36:53-60.
31. Matalon S, Schechtman S, Goldweig G, Ornoy A. The teratogenic effect of carbamazepine: A meta-analysis of 1,255 exposures. Reprod Toxicol 2002;16:9-17.
32. Nakane Y. Factors influencing the risk of malformations among infants of epileptic mothers. In: Janz D, Dam M, Richens A, Bossi L, Helge H (eds). Epilepsy, Pregnancy, and the Child. 2nd edn. New York: Raven Press, 1982, pp. 259-65.
33. Fairgrieve SD, Jackson M, Jonas P et al. Population based, prospective study of the care of women with epilepsy in pregnancy. BMJ 2000;321:674-75.
34. Lander CM, Eadie MJ. Antiepileptic drug intake during pregnancy and malformed offspring. Epilepsy Res 1990;7:77-82.
35. Berry RJ, Li Z, Erickson JD et al. Prevention of neural-tube defects with folic acid in China. New Engl J Med 1999;341:1485-90.
36. Ministry of Social Affairs and Health, Finland. Folic Acid and Neural Tube Defects. Letter of Ministry of Social Affairs and Health 33/623/95 Helsinki, 1995. In Finnish.
37. Schupf N, Ottman R. Reproduction among individuals with idiopathic/ cryptogenic epilepsy: Risk factors for spontaneous abortion. Epilepsia 1997;38:824-29.